Obesity is a chronic complex disease characterized by excessive adiposity that increases risk for multiple noncommunicable diseases including type 2 diabetes, cardiovascular disease, and some cancers.
Roche, AstraZeneca, and Eli Lilly announced large biotech licensing deals. The FDA advanced trial and Medicare initiatives, and CRISPR expanded Casgevy's label with CTX611 data due by year-end.
Science and Neurosoft partnered on brain-computer interface technology. Biocytogen licensed a fully human VHH antibody to Qilu Pharmaceutical; MassBio and SCbio selected 10 startups for Drive cohorts.
Eli Lilly's Phase 3b trials show the Taltz-Zepbound combination delivers sustained one-year improvements in skin clearance, psoriatic arthritis activity, and weight loss in adults with psoriatic disease and obesity, with no new safety concerns.
BMI normalization was linked to a 48.4% lower hazard of progression to stage 3 type 1 diabetes. A review of 46 studies found African indigenous foods may reduce inflammation in type 2 diabetes.
Forecasts show the obesity and diabetes drugs market expanding through 2035 on GLP-1 adoption, Europe's HIFU market reaching USD 65.57B by 2033, and AI precision medicine growing at a 31.3% CAGR.
A Cochrane meta-analysis of 22 studies with nearly 2,000 participants found intermittent fasting is not particularly effective for weight loss in obese or overweight adults and does not differ significantly from standard dietary advice. Experts note it remains an alternative at least as effective as classic calorie restriction, but more long-term trials are needed.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
A study in Life Metabolism shows that a single post-meal blood biomarker, 1-hour postprandial SPARC, predicts who benefits most from a Mediterranean diet. Lower baseline SPARC-1H levels were linked to greater improvements in insulin resistance and glucose control in a six-month trial.
New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07815678 |
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671 |
RECRUITING | PHASE1/PHASE2 |
| NCT07815067 |
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07812597 |
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07811895 |
Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer |
NOT_YET_RECRUITING | NA |
| NCT07810283 |
The Feasibility of Electrical Impedance Tomography to Guide Non-invasive Respiratory Interventions in Chronic Respiratory Disease |
ENROLLING_BY_INVITATION | |
| NCT07808073 |
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy |
NOT_YET_RECRUITING | PHASE1 |
| NCT07808060 |
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight |
NOT_YET_RECRUITING | PHASE1 |
| NCT07806851 |
UBT251 Injection Phase Ⅲ Study (OSA-PAP) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07806721 |
Family Grocery Study R01 |
NOT_YET_RECRUITING | NA |
| NCT07805291 |
Time Restricted Eating and Meal Frequency for Appetite Control |
COMPLETED | NA |
